Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
acetylcholine
alpha methyldopa hydrazine
amantadine
amitriptyline
amphetamines
anticholinergic drugs
anticholinergic drugs, side effects of
dementia
depression
dopamine
drug induced neurologic disorders
haloperidol
hypertension
imipramine
L-dopa
L-dopa, drug interactions with and side effects of
L-dopa, potentiators of
monoamine oxidase inhibitors
Parkinson disease
Parkinson disease, drug induced
Parkinson disease, treatment of
Parkinsonism syndrome
parsidol
phenothiazine
procyclidine
ritalin
tricyclic antidepressant
Showing articles 200 to 250 of 340 << Previous Next >>

Dopa-Responsive Dystonia:The Spectrum of Clinical Manifestations in a Large North American Family
Neurol 40:66-69, Nygaard,T.G.,et al, 1990

Levodopa-Induced Dyskinesia:Review, Observations, and Speculations
Neurol 40:340-345, Nutt,J.G., 1990

Selegiline as an Adjunct to Conventional Levodopa Therapy in Parkinson's Disease
Arch Neurol 46:1280-1283, Elizan,T.S.,et al, 1989

Swallowing Abnormalities and Their Response to Treatment in Parkinson's Disease
Neurol 39:1309-1314, Bushman,M.,et al, 1989

Controlled Release of Dopamine from a Polymeric Brain Implant:In Vivo Characterization
Ann Neurol 25:351-356, During,M.J.,et al, 1989

Lisuride, A Dopamine Agonist in the Treatment of Early Parkinson's Disease
Neurol 39:336-339, Rinne,U.K., 1989

A Double-Blind Crossover Comparison of Sinemet CR4 and Standard Sinemet 25/100 in Patients with Parkinson's Disease
JNNP 52:207-212, Cedarbaum,J.M.,et al, 1989

Efficacy of Sinemet CR4 in Subgroups of Patients with Parkinson's Disease
JNNP 52:83-88, Factor,S.A.,et al, 1989

Dose-Dependent Memory Impairment in Parkinson's Disease
Neurol 39:438-440, Huber,S.J.,et al, 1989

Continuous Levodopa Infusions to Treat Complex Dystonia in Parkinson's Disease
Neurol 39:888-891, Sage,J.I.,et al, 1989

Dopa Responsive Dystonia:A Treatable Condition Misdiagnosed as Cerebral Palsy
BMJ 298:1019-1020, Boyd,K.&Patterson,V., 1989

Amount and Distribution of Dietary Protein Affects Clinical Response to Levodopa in Parkinson's Disease
Neurol 39:552-556, Carter,J.H., 1989

The Effect of Dietary Protein on the Efficacy of L-Dopa:A Double-Blind Study
Neurol 39:549-552, Tsui,J.K.,et al, 1989

Diffuse Lewy Body Disease:Clinical Features in 15 Cases
JNNP 52:709-717, Byrne,E.J., 1989

Chronic Manganese Intoxication
Arch Neurol 46:1104-1106, Huang,C.C.,et al, 1989

International Symposium on Early Dopamine Agonist Therapy of Parkinson's Disease
Arch Neurol 45:204-208, Kurlan,R., 1988

Dystonia in Parkinson's Disease:Clinical & Pharmacological Features
Ann Neurol 23:73-78, Poewe,W.H.,et al, 1988

Neuroleptic-Induced Parkinson's Syndrome:Clinical Features and Results of Treatment with Levodopa
JNNP 51:850-854, Hardie,R.J.&Lees,A.J., 1988

Toluene Abuse Causes Diffuse Central Nervous System White Matter Changes
Ann Neurol 23:611-614, Rosenberg,N.L.,et al, 1988

Does Levodopa Aggravate Parkinson's Disease
Neurol 38:1410-1416, Blin,J.,et al, 1988

Duodenal and Gastric Delivery of Levodopa in Parkinsonism
Ann Neurol 23:589-595, Kurlan,R.,et al, 1988

Long-Term Duodenal Infusion of Levodopa for Motor Fluctuations in Parkinsonism
Ann Neurol 24:87-89, Sage,J.I.,et al, 1988

Controlled-Release Carbidopa/Levodopa (CR4-Sinemet) in Parkinson's Disease Pts With & Without Motor Fluctuations
Neurol 38:1143-1146, Goetz,C.G.,et al, 1988

Treatment of Chronic Parkinson's Disease with Controlled-Release Carbidopa/Levodopa
Arch Neurol 45:861-864, Hutton,J.T.,et al, 1988

Uneven Pattern of Dopamine Loss in the Striatum with Idiopathic Parkinson's Disease, Pathophysiologic & Clinical Implications
NEJM 318:876-880, Kish,S.J., 1988

Treatment of Restless Legs Syndrome & Periodic Movements During Sleep with L-Dopa:A Double-Blind, Controlled Study
Neurol 38:1845-1848, Brodeur,C.,et al, 1988

Cardiac Arrhythmias
In Handbook of Parkinson's Disease, W. C. Koller (ed) , Marcal Dekker, Inc, New York, 1987, p 151., , 1987

Controlled-Release Levodopa/Carbidopa. I. Sinemet CR3 Treatment of Response Fluctuations in Parkinson's Disease
Neurol 37:233-241, Cedarbaum,J.M.,et al, 1987

Controlled Release Levodopa Treatment of Motor Fluctuations in Parkinson's Disease
JNNP 50:194-198, Juncos,J.L.,et al, 1987

Factors that Influence the Occurrence of Response Variations in Parkinson's Disease
Ann Neurol 22:4-7, deJong,G.J.,et al, 1987

Multi-Center Study of Parkinson Mortality with Early Versus Later Dopa Treatment
Ann Neurol 22:8-12, Diamond,S.G.,et al, 1987

Early Combination of Bromocriptine & Levodopa in the Treatment of Parkinson's Disease:A 5-Year Follow-up
Neurol 37:826-828, Rinne,U.K., 1987

Forms of Dystonia in Patients with Parkinson's Disease
Neurol 37:1009-1011, Kidron,D.&Melamed,E., 1987

Parkinson's Disease & Motor Fluctuations:Long-Acting Carbidopa. Levodopa (CR-4-Sinemet)
Neurol 37:875-878, Goetz,C.G.,et al, 1987

Controlled-Release Levodopa/Carbidopa. II. Sinemet CR4 Treatment of Response Fluctuations in Parkinson's Disease
Neurol 37:1607-1612, Cedarbaum,J.M.,et al, 1987

Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations
Arch Neurol 44:1010-1012, Juncos,J.L.,et al, 1987

Dietary Influence on the Antiparkinsonian Response to Levodopa
Arch Neurol 44:1003-1005, Juncos,J.L.,et al, 1987

Progression of Parkinson's Disease Without Levodopa
Neurol 37:695-698, Coetz,C.G.,et al, 1987

Hereditary Dystonia-Parkinsonism Syndrome of Juvenile Onset
Neurol 36:1424-1428, Nygaard,T.C.&Duvoisin,R.C., 1986

Neurologic Sequelae of Chronic Solvent Vapor Abuse
Neurol 36:698-702, Hormes,J.T.,et al, 1986

Initiation of Levodopa Therapy in Parkinsonisn Patients Should be Delayed Until the Advanced Stages of the Disease
Arch Neurol 43:402-407, Melamen,E., 1986

Modification of Parkinson's Disease by Long-Term Levodopa Treatment
Arch Neurol 43:405-407, Markham,C.H.&Diamond,S.G., 1986

Painful Parkinson's Disease
Lancet 1:1366-1369, Quinn,N.P.,et al, 1986

Levodopa in Restless Legs
Lancet 2:426-427, vonScheele,C., 1986

Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986

A Neuroleptic Malignantlike Syndrome Due to Levodopa Therapy Withdrawal
JAMA 254:2792-2795, Friedman,J.H.,et al, 1985

Low Dosages of Bromocriptine Added to Levodopa in Parkinson's Disease
Neurol 35:199-206, Maier,M.M.,et al, 1985

Hyperthermia after Discontinuance of Levodopa & Bromocriptine Therapy:Impaired Dopamine Receptors a Possible Cause
Neurol 35:258-261, Figa-Talamanca,L.,et al, 1985

Development of Malignant Melanoma after Levodopa Therapy for Parkinson's Disease, Report of Case & Review
Am J Med 79:119-121, Kochar,A.S., 1985

Levodopa & Melanoma:Three Cases & Review of Literature
JNNP 48:585-588, Rampen,F.H.J., 1985



Showing articles 200 to 250 of 340 << Previous Next >>